Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.

vaccine
Pfizer expects new vaccines to deliver a boost to revenues • Source: Shutterstock

Pfizer Inc. has several launches planned for the second half of the year, including the new vaccine Abrysvo for respiratory syncytial virus (RSV) in older adults, the bispecific antibody elranatamab for multiple myeloma, etrasimod for ulcerative colitis and expansion of the pneumococcal vaccine Prevnar 20 to the pediatric population – a larger commercial opportunity versus adults.

Pfizer CEO Albert Bourla told investors during the company’s first quarter sales and earnings call on 2 May that revenues...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.